Sichuan Biokin Pharmaceutical Co., Ltd.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a decline in stock value, reflecting ongoing financial challenges. The company reported significant negative net sales growth and a substantial drop in net profit over the past nine months. Liquidity concerns are evident, with low operating cash flow and a market capitalization of CNY 29,530 million.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a significant stock decline today, reflecting ongoing market volatility. The company has reported negative results for four consecutive quarters, with a substantial drop in net sales and a notable loss in net profit. Its market capitalization stands at CNY 29,530 million.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant rise in its stock on March 16, 2026, reaching an intraday high. The company has shown resilience with a recent weekly increase, although its year-to-date performance remains negative. It maintains a strong annual growth rate despite facing recent financial challenges.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a significant stock decline today, reflecting ongoing market challenges. Over the past month, the stock has dropped notably, with year-to-date losses also evident. Recent quarterly results showed substantial declines in net sales and profit, raising concerns about the company's financial health.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with a slight increase in the China Shanghai Composite. Despite a recent weekly gain, the company faces challenges with a substantial drop in net sales and a notable net profit loss, impacting its market position in the pharmaceuticals sector.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a notable stock price increase on March 10, 2026, contrasting with the modest rise of the China Shanghai Composite. Despite recent volatility, the company has achieved substantial long-term growth, significantly outpacing the broader market over the past three years. Its market capitalization is CNY 29,530 million.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant rise in its stock today, contrasting with a decline in the broader market. Despite this uptick, the company has struggled financially, reporting substantial decreases in net sales and profits over the past nine months, alongside a notable year-to-date decline.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Over the past week and month, the stock has faced notable decreases, and year-to-date figures reflect ongoing challenges. Financial metrics indicate negative growth and a substantial drop in net profit.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. The company has struggled over the past week and year-to-date, facing negative results in recent quarters, including drops in net sales and profit, amid challenging financial metrics.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a significant stock decline on February 25, 2026, marking a challenging trading session. The company has experienced a year-to-date drop, with net sales and profits also declining sharply. Despite past growth, it now navigates a difficult market environment.